TherapeuticsMD (TXMD) Given a $26.00 Price Target at Cantor Fitzgerald

Cantor Fitzgerald set a $26.00 target price on TherapeuticsMD (NASDAQ:TXMD) in a research report released on Monday morning. The brokerage currently has a buy rating on the stock.

Several other equities analysts also recently commented on the stock. ValuEngine raised shares of TherapeuticsMD from a strong sell rating to a sell rating in a research note on Monday, April 2nd. Oppenheimer set a $10.00 price objective on shares of TherapeuticsMD and gave the company a buy rating in a research note on Thursday, May 3rd. Zacks Investment Research downgraded shares of TherapeuticsMD from a hold rating to a sell rating in a research note on Wednesday, April 25th. JPMorgan Chase & Co. began coverage on shares of TherapeuticsMD in a research note on Friday, June 15th. They issued an overweight rating and a $11.00 price target for the company. Finally, BidaskClub downgraded shares of TherapeuticsMD from a hold rating to a sell rating in a research note on Tuesday, July 3rd. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eight have given a buy rating to the stock. TherapeuticsMD has a consensus rating of Buy and an average target price of $14.38.

Shares of TherapeuticsMD traded up $0.06, hitting $5.24, during midday trading on Monday, MarketBeat.com reports. 285,920 shares of the stock traded hands, compared to its average volume of 1,662,167. The company has a market cap of $1.13 billion, a price-to-earnings ratio of -14.00 and a beta of 1.54. The company has a current ratio of 7.88, a quick ratio of 7.51 and a debt-to-equity ratio of 0.94. TherapeuticsMD has a one year low of $4.34 and a one year high of $7.66.

TherapeuticsMD (NASDAQ:TXMD) last issued its quarterly earnings data on Monday, July 30th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.03). The firm had revenue of $3.80 million for the quarter, compared to the consensus estimate of $4.23 million. TherapeuticsMD had a negative net margin of 582.86% and a negative return on equity of 80.75%. The business’s revenue was down 11.6% on a year-over-year basis. During the same period last year, the company posted ($0.10) earnings per share. research analysts forecast that TherapeuticsMD will post -0.51 EPS for the current fiscal year.

Hedge funds have recently added to or reduced their stakes in the stock. Xact Kapitalforvaltning AB raised its stake in TherapeuticsMD by 96.3% in the first quarter. Xact Kapitalforvaltning AB now owns 31,800 shares of the company’s stock worth $155,000 after buying an additional 15,600 shares in the last quarter. Geode Capital Management LLC raised its stake in TherapeuticsMD by 19.7% in the fourth quarter. Geode Capital Management LLC now owns 1,606,780 shares of the company’s stock worth $9,704,000 after buying an additional 264,421 shares in the last quarter. MetLife Investment Advisors LLC bought a new position in TherapeuticsMD in the fourth quarter worth about $423,000. California State Teachers Retirement System raised its stake in TherapeuticsMD by 4.5% in the fourth quarter. California State Teachers Retirement System now owns 261,142 shares of the company’s stock worth $1,577,000 after buying an additional 11,317 shares in the last quarter. Finally, Deutsche Bank AG raised its stake in TherapeuticsMD by 147.3% in the fourth quarter. Deutsche Bank AG now owns 378,841 shares of the company’s stock worth $2,286,000 after buying an additional 225,663 shares in the last quarter. 72.73% of the stock is owned by institutional investors.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.

Featured Story: Earnings Per Share (EPS)

Analyst Recommendations for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply